Clinical research

Oncology clinical trials Speech and language science Phase 3 oncology trials Randomized controlled trials

FDA Approves Tecentriq With Chemotherapy for Stage III dMMR Colon Cancer

ATOMIC phase 3 data showing a halving of recurrence risk support a move to add immunotherapy to post‑surgery care for this molecular subgroup.

FDA Approves Tucatinib as Chemotherapy‑Free Maintenance for Advanced HER2‑Positive Breast Cancer

Epcoritamab With R‑CHOP Cuts Progression Risk 51% in First‑Line DLBCL Trial